Q-omics provides the consensus-scored B3GNT4 profile across patient tissues and cancer cell-line models. B3GNT4 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, B3GNT4 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, B3GNT4 RNA expression shows 18,415 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where B3GNT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GNT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GNT4 survival associations across molecular data types. B3GNT4 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GNT4 RNA expression–survival associations across cancer types. High B3GNT4 expression shows unfavorable associations in ACC, MESO, HNSC, COAD, SKCM and UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for B3GNT4 RNA expression.
This table summarizes B3GNT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for B3GNT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GNT4 shows higher tumor expression in KIRC, HNSC, LUAD, COAD, LUSC and BLCA. The KIRC box plot shows higher B3GNT4 RNA expression in tumor versus normal tissue (log2 FC = +2.273, t-test p < 0.001).
This table shows molecular features associated with B3GNT4 in patient tissues and cancer cell lines. In patient samples, B3GNT4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GNT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
